1. Home
  2. PAHC vs NTLA Comparison

PAHC vs NTLA Comparison

Compare PAHC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAHC
  • NTLA
  • Stock Information
  • Founded
  • PAHC 1946
  • NTLA 2014
  • Country
  • PAHC United States
  • NTLA United States
  • Employees
  • PAHC N/A
  • NTLA N/A
  • Industry
  • PAHC Biotechnology: Pharmaceutical Preparations
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • PAHC Health Care
  • NTLA Health Care
  • Exchange
  • PAHC Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • PAHC 968.3M
  • NTLA 794.5M
  • IPO Year
  • PAHC 2014
  • NTLA 2016
  • Fundamental
  • Price
  • PAHC $29.49
  • NTLA $11.89
  • Analyst Decision
  • PAHC Hold
  • NTLA Buy
  • Analyst Count
  • PAHC 4
  • NTLA 19
  • Target Price
  • PAHC $24.50
  • NTLA $35.11
  • AVG Volume (30 Days)
  • PAHC 341.9K
  • NTLA 4.2M
  • Earning Date
  • PAHC 08-27-2025
  • NTLA 08-07-2025
  • Dividend Yield
  • PAHC 1.63%
  • NTLA N/A
  • EPS Growth
  • PAHC 140.17
  • NTLA N/A
  • EPS
  • PAHC 0.78
  • NTLA N/A
  • Revenue
  • PAHC $1,190,682,000.00
  • NTLA $45,569,000.00
  • Revenue This Year
  • PAHC $28.13
  • NTLA N/A
  • Revenue Next Year
  • PAHC $13.11
  • NTLA N/A
  • P/E Ratio
  • PAHC $37.79
  • NTLA N/A
  • Revenue Growth
  • PAHC 19.12
  • NTLA N/A
  • 52 Week Low
  • PAHC $16.16
  • NTLA $5.90
  • 52 Week High
  • PAHC $31.80
  • NTLA $27.77
  • Technical
  • Relative Strength Index (RSI)
  • PAHC 64.77
  • NTLA 67.14
  • Support Level
  • PAHC $29.64
  • NTLA $11.31
  • Resistance Level
  • PAHC $31.71
  • NTLA $12.34
  • Average True Range (ATR)
  • PAHC 1.07
  • NTLA 0.76
  • MACD
  • PAHC -0.01
  • NTLA 0.09
  • Stochastic Oscillator
  • PAHC 69.12
  • NTLA 91.88

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: